Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Gülfe, Anders LU ; KARLSSON WALLMAN, JOHAN LU and Kristensen, Lars Erik (2016) In Arthritis Research and Therapy 18(1).
Abstract
The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Arthritis Research and Therapy
volume
18
issue
1
article number
51
publisher
BioMed Central (BMC)
external identifiers
  • pmid:26892115
  • scopus:84959449364
  • wos:000370836900001
  • pmid:26892115
ISSN
1478-6362
DOI
10.1186/s13075-016-0950-0
language
English
LU publication?
yes
id
78e36753-0dbd-4f59-831c-f8468e5fe341 (old id 8825071)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26892115?dopt=Abstract
date added to LUP
2016-04-04 08:11:53
date last changed
2022-04-23 17:11:02
@article{78e36753-0dbd-4f59-831c-f8468e5fe341,
  abstract     = {{The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.}},
  author       = {{Gülfe, Anders and KARLSSON WALLMAN, JOHAN and Kristensen, Lars Erik}},
  issn         = {{1478-6362}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Arthritis Research and Therapy}},
  title        = {{EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.}},
  url          = {{http://dx.doi.org/10.1186/s13075-016-0950-0}},
  doi          = {{10.1186/s13075-016-0950-0}},
  volume       = {{18}},
  year         = {{2016}},
}